n | 446 |
Age | 52 (18–87) |
Sex, male/female | 268/178 |
Body mass index (kg/m2) | 26.3 (18.1–42.4) |
History of liver cancer, yes/no | 29/416 |
History of non-liver malignancy, yes/no | 39/405 |
Type 2 diabetes mellitus, yes/no | 147/297 |
Dyslipidemia, yes/no | 151/294 |
Hypertension, yes/no | 200/246 |
Hyperuricemia, yes/no | 46/399 |
Smoking, yes/no | 98/338 |
Albumin (g/dL) | 4.1 (2.8–6.9) |
Aspartate aminotransferase (IU/L) | 44 (12–378) |
Alanine aminotransferase (IU/L) | 69 (13–783) |
Gamma-glutamyl transpeptidase (IU/L) | 71 (11–990) |
Hemoglobin (g/dL) | 14.6 (6.5–18.7) |
Platelet count (× 104/μL) | 21.2 (4.0–47.1) |
Triglyceride (mg/dL) | 139 (31–1088) |
Total cholesterol (mg/dL) | 203 (101–370) |
High-density lipoprotein cholesterol (mg/dL) | 45 (14–86) |
Low-density lipoprotein cholesterol (mg/dL) | 121 (27–243) |
Fasting blood sugar (mg/dL) | 103 (65–287) |
Glycated hemoglobin (%) | 6.0 (4.3–12.6) |
Ferritin (ng/mL) | 228 (1–2067) |
NAFLD fibrosis score | − 1.844 (− 7.060 to 3.394) |
Genetic variation (n = 314) | |
PNPLA3 rs738409, CC/CG/GG/not done | 54/129/131/132 |
TM6SF2 rs58542926, CC/CT/TT/not done | 237/70/7/132 |
HSD17B13 rs6834314, AA/AG/GG/not done | 161/132/25/128 |
Histopathological findings (n = 446) | |
Steatosis, 5%–33%/ 33%–66%/> 66% | 164/167/112 |
Ballooning, none/few cells/many cells | 40/283/120 |
Lobular inflammation, no foci/< 2 foci/2–4 foci/> 4 foci per 200 × field | 28/254/147/14 |
NAFLD activity score, ≤ 2/3,4/≥ 5 | 35/190/218 |
Fibrosis stage, 0/1/2/3/4 | 51/182/69/110/34 |